Who founded Engage Bio?

Engage Bio was founded by Will Olsen in 2021.

Who are Engage Bio's investors?

Engage Bio's investors include CAL Innovation, California Innovation Fund, Gaingels, Metaplanet, SciFounders, VentureSouq, WorldQuant Ventures, xfactor ventures and 9 more.

Where is Engage Bio headquartered?

Engage Bio is headquartered in San Francisco, US.

Engage Bio

AcquiredYC W22

San Francisco, US · Founded 2021 · 10 employees · 17 known investors

Find your way into Engage Bio

Paths you didn't know you had: your email and LinkedIn already hold routes to the Engage Bio team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

EngageBio develops DNA-based medicines using proprietary non-viral delivery technology to achieve extended therapeutic expression from a single dose with low manufacturing complexity.

Also known as Engage Biologics Inc.

Biotech Digital Health Healthtech Synthetic Biology Healthcare Therapeutics Drug discoveryUnited States of AmericaAmerica / Canada

Founders & leadership· Y Combinator alumni (W22)

Engage Bio was founded in 2021 by Will Olsen.

Will OlsenFounderWill Olsen is co-founder and CEO of Engage Bio.

Kathryn Kwant

Investors · 17

CAL Innovationlisted by CAL InnovationMill Valley

How we know: Y Combinator's founder network · Not right? Tell us

California Innovation Fundlisted by California Innovation FundBerkeley

How we know: California Innovation Fund's portfolio page · Not right? Tell us

Gaingelslisted by GaingelsNew York · $200K – $500K

How we know: gaingels.com · Not right? Tell us

Metaplanetlisted by MetaplanetTallinn · $500K – $10M

How we know: Metaplanet's portfolio page · the VCSheet dataset · Not right? Tell us

SciFounderslisted by SciFoundersSan Francisco · $1M

How we know: SciFounders's portfolio page · funding news · the VCSheet dataset · Y Combinator's founder network · Not right? Tell us

VentureSouqlisted by VentureSouqAbu Dhabi · $100K – $10M

How we know: Y Combinator's founder network · venturesouq.com · Not right? Tell us

WorldQuant Ventureslisted by WorldQuant VenturesOld Greenwich

How we know: the VCSheet dataset · open dataset · 5k.vc investor directory · Y Combinator's founder network · Not right? Tell us

xfactor ventureslisted by xfactor venturesDedham · $100K – $200K

How we know: xfactor ventures's portfolio page · Y Combinator's founder network · Not right? Tell us

Y Combinatorlisted by Y CombinatorSan Francisco · $500K

How we know: the Y Combinator directory · open dataset · 5k.vc investor directory · Not right? Tell us

10X CapitalreportedNew York

How we know: Y Combinator's founder network · Not right? Tell us

AJGreported

How we know: Y Combinator's founder network · Not right? Tell us

Forward Deployed VCreported

How we know: Y Combinator's founder network · Not right? Tell us

General Advancereported

How we know: Y Combinator's founder network · Not right? Tell us

PioneerreportedToronto, Ontario

How we know: Y Combinator's founder network · open dataset · 5k.vc investor directory · Not right? Tell us

Red Rooster VenturesreportedSan Mateo

How we know: Y Combinator's founder network · Not right? Tell us

SAV (Scale Asia Ventures)reportedPalo Alto · $100K – $25M

How we know: Y Combinator's founder network · Not right? Tell us

Funding

SEC filings, press & company announcements

Undisclosed amountSeedJul 2024
Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

Related companies · 7

ParcelBioParcelBio develops APEXm, a proprietary mRNA platform that enhances protein expression for longer-lasting therapeutic effect compared to conventional mRNA technologies. The platform targets autoimmune disease, oncology, and therapeutic protein replacement applications.

Abalone BioAbalone Bio develops activating antibodies (agonists) targeting hard-to-drug receptors such as G-protein coupled receptors, using engineered cells to measure antibody pharmacological activity at high throughput combined with machine learning. Its initial focus is cell-specific antibody drugs for obesity and metabolic disease aimed at avoiding the GI side effects associated with GLP-1 therapies.

ACXACX develops bioengineered solutions for pest control in agriculture, replacing synthetic chemicals with precision biocides. The company serves crop producers and aims to enhance food security while reducing chemical dependence and promoting biodiversity.

BridgebioBridgeBio develops treatments for genetic conditions and cancers using a decentralized hub-and-spoke model, where autonomous teams focus on specific diseases or drug candidates while a central hub provides clinical, regulatory, and commercial support. The company partners with academic institutions to advance early-stage research toward late-stage clinical trials.

SynviviaSynvivia develops chemical control technology over cell behavior to optimize the biomanufacturing of high-value biopharmaceutical products. It operates in the synthetic biology and drug discovery space.

Granza BioGranza Bio develops immunotherapy treatments leveraging naturally-occurring attack particles that are released from cytotoxic immune cells to target diseases including cancers, autoimmunity, and infections.

GentiBioGentiBio develops engineered regulatory T-cell (EngTreg) therapies designed to reset the immune system and treat autoimmune and acute inflammatory diseases. The company builds autologous and allogeneic Treg platforms as an alternative to systemic immune-suppressive therapies.

Companies working in the same space as Engage Bio.

Legal entities · 1

corporate structure

Engage Biologics Inc.

In the news

Lilly and Engage Bio tie the knot with $202M acquisition - BioSpacebiospace.com · May 2026

Engage Bio Acquired by Lilly to Accelerate Development of Non-Viral Genetic Medicines - AOLaol.com · May 2026

Frequently asked questions

What does Engage Bio do?: EngageBio develops DNA-based medicines using proprietary non-viral delivery technology to achieve extended therapeutic expression from a single dose with low manufacturing complexity.
Who founded Engage Bio?: Engage Bio was founded by Will Olsen in 2021.
Who are Engage Bio's investors?: Engage Bio's investors include CAL Innovation, California Innovation Fund, Gaingels, Metaplanet, SciFounders, VentureSouq, WorldQuant Ventures, xfactor ventures and 9 more.
Where is Engage Bio headquartered?: Engage Bio is headquartered in San Francisco, US.